SBP target of lower than 120 mmHg reduces CV events in T2DM

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

LDL-C Management Trends in ASCVD Patients
LDL-C Management Trends in ASCVD Patients
Heart Matters
LDL-C Management Trends in ASCVD Patients
- Keith C. Ferdinand, MD, FACC, FAHA , FASPC, FNLA, FPCNA
Bempedoic acid reduces adverse limb events in patients with PAD
Bempedoic acid reduces adverse limb events in patients with PAD
Heart Matters
Bempedoic acid reduces adverse limb events in patients with PAD
- Marc Bonaca, MD
Tirzepatide reduces HF events in patients with HFpEF and obesity
Tirzepatide reduces HF events in patients with HFpEF and obesity
Heart Matters
Tirzepatide reduces HF events in patients with HFpEF and obesity
- Milton Packer, MD
Edoxaban as alternative to warfarin after bioprosthetic valve surgery
Edoxaban as alternative to warfarin after bioprosthetic valve surgery
Heart Matters
Edoxaban as alternative to warfarin after bioprosthetic valve surgery
- Chisato Izumi, MD, PhD

SBP target of lower than 120 mmHg reduces risk of CV events in T2DM